Vancouver company receives federal licence to work with all natural psychedelics, including ayahuasca – The GrowthOp

Breadcrumb Trail Links

This is a promising step forward in our mission to get safe, natural psychedelics into the hands of everyone who needs them, as soon as possible.

Author of the article:

Vancouver-based Filament Health, a natural psychedelic drug development company, has expanded the scope of its research.

The company was already federally licensed to work with psychoactive mushrooms, but an amendment to its Health Canada Dealers Licence will now allow Filament to possess, produce, research, export and import all remaining controlled natural psychedelic substances, including N,N-dimethyltryptamine (DMT) and mescaline.

This licence amendment significantly increases the scope of our work with natural psychedelics, said Filaments director of research, Ryan Moss. By studying untapped psychedelics in a scientific setting, we believe we can unlock and standardize their healing power. This is a promising step forward in our mission to get safe, natural psychedelics into the hands of everyone who needs them, as soon as possible, Moss said.

Filament plans to produce natural extracts of these substances at its facility in Metro Vancouver and enter them into clinical trials to demonstrate safety and efficacy.

The benefits of these valuable plants are well-documented; we will be among the first to purposefully explore their pharmaceutical applications, said company CEO Benjamin Lightburn.

In June, the company announced its natural psilocybin extracts would be administered in clinical trials in collaboration with the Translational Psychedelic Research Program at the University of California, San Francisco, later this year.

Another Vancouver-based company, Algernon Pharmaceuticals, is also studying DMT, a psychedelic compound that is part of the tryptamine family, alongside substances like psilocybin, ketamine and LSD, as a possible treatment option for stroke.

The Phase 1 clinical trial, which will seek to establish dosages and the safety of the treatment, is set to begin later this year with U.K.-based Hammersmith Medicines Research, a contract research organization that specializes in clinical pharmacology.

One of the consultants on the trial is Dr. David Nutt, a psychiatrist and a neuropsychopharmacology professor at Imperial College London and formerly the U.K. governments top drug adviser.

The idea is, can we stimulate neurogenesis without being psychedelic? Dr. Nutt told The GrowthOp earlier this year. I think thats a really clever idea. No one knows. But if it works, its very exciting.

We apologize, but this video has failed to load.

Subscribe toWeekend Dispensary, a new weekly newsletter from The GrowthOp.

Here is the original post:

Vancouver company receives federal licence to work with all natural psychedelics, including ayahuasca - The GrowthOp